Controlled trial of oral contraceptives in haemophilia

Brandt, N.J.; Cohn, J.; Hilden, M.; Brandt, N.J; Cohn, J; Hilden, M

doi:10.1111/j.1600-0609.1973.tb00121.x

Home

>

Node

>

Subnode

Controlled trial of oral contraceptives in haemophilia

Brandt, N.J.; Cohn, J.; Hilden, M.

Scandinavian Journal of Haematology 11(3): 225-229

1973

ISSN/ISBN: 0036-553X

PMID: 4587789

DOI: 10.1111/j.1600-0609.1973.tb00121.x

Document Number: 491529

In a 6-month controlled trial, 18 boys with hemophilia were treated with combined estrogens and progesterone (Lyndiol). Findings showed a reduction in bleeding of skin and joints, a minor shortening of coagulation time in glass and plastic, a decrease in kaolin-cephalin time, and a significant increase in fibrinogen (p-value.041), and factor II and VII levels (p-value.001). However, the treatment did not affect the number of days in bed, hematuria, epistaxis, or muscular bleeding. All patients developed severe side-effects (gynecomastia and pubic hair), therefore, this treatment is not recommended in management of hemophilia in boys.